New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The cGMP-4 facility will further strengthen the company's ability to serve global partners
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The facility has been designed with a dual focus on efficiency and sustainability
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Subscribe To Our Newsletter & Stay Updated